Cell & Gene
Manufacturing CGTs: Should I Use A CDMO?
September 30, 2022
Sidley lawyers Deeona Gaskin and Raj Pai recently published an article in Cell & Gene entitled “Manufacturing CGTs: Should I Use A CDMO?” The article explains various manufacturing challenges faced by sponsors of cell and gene therapies, and considerations for companies looking to outsource manufacturing of their cell and gene therapy products to contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs).
Contacts
Related Blogs
Capabilities
Suggested News & Insights
A More Competitive MedTech Landscape in the EU? What the MDR/IVDR Revision Could Mean for MedTech Manufacturers and InvestorsOctober 16, 20262025 to First-Half 2026 Marks a Breakout Time for CVRsOctober 7, 2026EU Biotech Act I: Parliament and Council back Europe’s biotech competitiveness agenda – SPC incentive now the key battlegroundSeptember 21, 2026HHS Secretary Announces Intent to Extend HHS-OIG Exclusion Authority to CMS, Expanding the Administration’s Anti-Fraud CampaignSeptember 16, 2026When AI Changes The Deal: Seven AI-related Considerations for Life Sciences M&A DealmakersSeptember 8, 2026Is my product a medical device? EU Court judgment clarifies that the test includes objective function and intended purpose, and provides guidance relevant to software and AI-enabled toolsAugust 31, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory